APA (7th ed.) Citation

Abbink, K., Zusterzeel, P. L., Geurts-Moespot, A. J., Herwaarden, A. E. v., Pijnenborg, J. M., Sweep, F. C., & Massuger, L. F. (2018). HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. SAGE Publishing.

Chicago Style (17th ed.) Citation

Abbink, Karin, Petra LM Zusterzeel, Anneke J. Geurts-Moespot, Antonius E van Herwaarden, Johanna MA Pijnenborg, Fred CGJ Sweep, and Leon FAG Massuger. HE4 Is Superior to CA125 in the Detection of Recurrent Disease in High-risk Endometrial Cancer Patients. SAGE Publishing, 2018.

MLA (9th ed.) Citation

Abbink, Karin, et al. HE4 Is Superior to CA125 in the Detection of Recurrent Disease in High-risk Endometrial Cancer Patients. SAGE Publishing, 2018.